Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Distinctive Molecular Risk Factors Between MDS and MDS/AML Defined by ICC.

American journal of hematology - 1 Jun 2026

Zhang Ting-Juan, Zhao Yang-Jing, Xu Zi-Jun, Qian Jun, Zhou Jing-Dong

Abstract excerpt

Myelodysplastic syndromes/neoplasms (MDS) represent a heterogeneous group of clonal hematopoietic stem cell diseases with high risks of acute myeloid leukemia (AML) transformation. To emphasize the characteristics of AML transformation, the International Consensus Classification (ICC) has classified MDS with excess blasts (10%-19%) as MDS/AML. Recently, a clinical-molecular prognostic model International...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over
Share to fms-Like Tyrosine Kinase 3

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Myeloid, Acute

Share to Myelodysplastic Syndromes

Share to Prognosis

Share to Risk Factors

Share to Tumor Suppressor Protein p53

Source

Identifiers

PMID: 41913093
DOI: 10.1002/ajh.70296

Genes

FLT3
TP53

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Distinctive Molecular Risk Factors Between MDS and MDS/AML Defined by ICC.PMID 41913093Read ↗

Validation of the molecular international prognostic scoring system in patients with myelodysplastic syndromes defined by international consensus classification.Semantic proximity Read ↗

Clinico-genetic and prognostic analyses of 716 patients with primary myelodysplastic syndrome and myelodysplastic syndrome/acute myeloid leukemia based on the 2022 International Consensus Classification.Semantic proximity Read ↗

Validation of the Molecular International Prognostic Scoring System in Patients with Myelodysplastic Syndromes Defined by International Consensus ClassificationSemantic proximity Read ↗

Molecular International Prognostic Scoring System for Myelodysplastic Syndromes.Semantic proximity Read ↗

When to use which molecular prognostic scoring system in the management of patients with MDS?Semantic proximity Read ↗

Molecular landscape of myelodysplastic neoplasms in disease classification and prognostication.Semantic proximity Read ↗

Integration of genomic and clinical variables improves the prediction of myelodysplastic syndromes to acute myeloid leukaemia transformation and prognosis.Semantic proximity Read ↗

How I treat higher-risk MDSSemantic proximity Read ↗

The International Consensus Classification of myelodysplastic syndromes and related entities.Semantic proximity Read ↗

Comparative Analysis of ICC and WHO Classifications Reveals Molecular and Clinical Convergence Between AML-MR and MDS/AML.Semantic proximity Read ↗

Myelodysplastic syndromes classification and risk stratification.Semantic proximity Read ↗

[Molecular international prognostic scoring system for myelodysplastic syndromes].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.